Text Size

Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model

Jauhonen H.-M., Laihia J., Oksala O., Viiri J., Sironen R., Alajuuma P., Kaarniranta K., Leino L.


  • 2017
  • Graefe's Archive for Clinical and Experimental Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Preclinical development

  • Affiliations

    Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland; Institute of Clinical Medicine, Department of Ophthalmology, University of Eastern Finland, Kuopio, Finland; Department of Ophthalmology, University of Eastern Finland and Kuopio University Hospital, Finland, P.O. Box 1627, Kuopio, FIN-70211, Finland; BioCis Pharma Ltd, Turku, Finland; Santen Oy, Tampere, Finland; Institute of Clinical Medicine, Department of Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland; Department of Pathology, Kuopio University Hospital, Kuopio, Finland

Related Publications

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.


Correlation between gene expression and clinical scores in vernal keratoconjunctivitis

Leonardi A, Cavarzeran F, Rosani U, Righetti G, Garrigue JS, Brun P.


Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

Leonardi A, Doan S, Aragona P,  Amrane M, Ismail D, Montero J, Németh J, Bremond-Gignac D


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022